A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA (Tolvaptan)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 10 Oct 2017 This trial has been completed in Czech Republic, according to European Clinical Trials Database
- 21 Sep 2017 Planned End Date changed from 1 May 2020 to 1 Oct 2017.
- 21 Sep 2017 Planned primary completion date changed from 1 May 2020 to 1 Oct 2017.